LETTERS TO THE EDITOR
tently seen in the patients in which the hyperemias were accessible for reliable rCBF investigations, we found it justified to discuss therapeutical possibilities.
Our assumption of hyperemic borderzone as threatened areas with a potential to survive is derived from our own findings of impaired autoregulation, false autoregulation, and impaired C0 2 -response in some of the hyperemic areas investigated. Experimental findings of histopathological changes in hyperemic brain tissue are available and quoted in the paper. Early surgical recanalisation of occluded arteries in stroke are known sometimes to produce hemorrhagic infarction and worsening the clinical outcome. Unlike other organs, the brain is placed within a closed skull. Focally increased blood volume and edema affect, therefore, the tissue pressure in the surrounding tissue much more in the brain than in other organs. Finally the type of hyperemia reported in our study seems to disappear within the first week after the stroke. It is not comparable to the hyperemias seen 2-4 weeks after the stroke which serves in the reabsorption process of necrotic material from the infarct.
Much work remains before the nature and clinical significance of cerebral hyperemia is clarified. The findings in our study indicate that acute cerebral infarction is not only a matter of cerebral ischemia. Hyperemia is quite as common and the entire infarct is sometimes even hyperemic without being hemorrhagic. We find it worthwhile to include the presence of focal hyperemia in therapeutical considerations. The opening sentence of the article implies that progressing strokes are defined by their progression over minutes. When questioned closely, patients with strokes of apparently "sudden" onset will often describe an evolution of their symptoms over minutes. We feel that progressing strokes are better defined as showing deterioration over hours though the process is usually completed within one day. Deterioration over days on the other hand is also seen in a large minority of acute stroke patients.' The pathogenesis of these three evolutionary types of acute stroke may be the determining factor in their differing temporal profiles.
The authors state that anticoagulants may be helpful in progressing ischemic strokes but the implied progressing "thrombosis" may be a theoretical concept which needs revising. Cerebral edema is the most powerful adverse factor in the first few days of acute cerebral infarction and serial CT scans in such patients in the acute and sub-acute periods usually show no extension of the area of infarction.
Patients who progress or deteriorate in the acute stage usually reveal a mass effect of brain swelling on CT, the suddenness simply representing mechanical decompensation within the bony confines of the skull. Models of experimental brain edema suggest that more edema accumulates outside than inside the infarction once the blood-brain barrier has been breeched. Attacking this problem may prove more fruitful than using To the Editor:
The letter from Drs. Norris and Lassen provides an opportunity to emphasize again three of the many points made in our article "Treatment of Progressing Stroke."' 1. Over the decades it has become apparent that many physicians have a problem in dealing with the concept of the minute to minute uncertainty produced by the changing quality and quantity of neurological deficit which is the hallmark of "progressing stroke" (stroke-inevolution). Physicians who deal with acute illness in patients in intensive care units soon become familiar with the notion of frequent reexamination (every 30 minutes in our cerebrovascular intensive care unit) of the salient abnormality. Thus, a determination can be made as to whether the trouble is worsening, static or improving. For instance, a patient seen at 10 a.m. with mild left upper extremity weakness (history of onset at 9 a.m. that day), re-examined at 10:30 a.m. and found to have severe weakness of that extremity, would be classified as "progressing stroke," but if the deficit had disappeared the categorization would be "transient ischemic attack." The clinical stage designation may change several times for the same patient. This extreme variability in the natural history, when added to the diverse pathogenetic mechanisms causing the focal situation, admittedly does produce a complex set of variables with which the physician must grapple.
In our review, we wrote that "18 to 24 hours without progression is needed to be sure that further progression is unlikely," for infarction in brain supplied by the carotid system, while in "the vertebrobasilar system a longer period (up to 72 hours), should pass.' This natural history is so variable that we included numerous details to illustrate those differences.
2. The use of anticoagulant, to prevent progression, is only recommended when there is accurate diagnosis and there is incomplete impairment of function. If the patient is hemiplegic and/or has a depressed level of consciousness, it can be assumed that maximum ischemia is probably past and progression of focal ischemia is unlikely. In this situation, it is not advisable to start heparin. In a number of centers, where there is extensive experience with acute occlusive stroke, anticoagulant therapy is used frequently. 23 - 4 3. Cerebral edema which can follow cerebral infarction is the most serious threat to life. In the same issue of "Stroke" in which our paper appeared, Bounds et al. 5 reported that transtentorial herniation was the cause of death in 31% of 100 cases of acute cerebral infarction in the brain supplied by the internal carotid artery studied at autopsy, and 60% had some other cause of death. At that same cerebrovascular center the mortality for acute occlusive disease stroke (carotid system) is 11%. Those who work with animal models of experimental brain edema are working with and producing severe lesions. This is an entirely different population than patients with stroke coming to a clinical cerebrovascular service. In the latter situation, many patients have minimum focal brain damage when admitted -the objective is to keep focal brain damage from progressing to an extreme state as often represented by the experimental brain edema models.
A number of therapies are reviewed in our paper for treatment of progressing stroke -selection must be made depending on the mecha- 
